







FIP Foundation for Education and Research
ANNUAL REPORT 2020







In memory of John Ware, chairman of the FIP Foundation from 2016 to 2020.

Remembering John's dedication, energy and contributions to pharmacy. He will be greatly missed by the international pharmacy world.

### **FOREWORD**



Writing this foreword and reflecting on 2020 has caused a wealth of emotions, both positive and negative.

I know the pandemic has been extremely challenging for all of us — both in our personal lives and professional work. However, numerous new opportunities and advancements have also occurred as unique approaches and solutions were needed in a pandemic world. These statements also apply very directly to the work of the foundation over the past year.

Our board of committed leaders from around the globe have worked together as a team through many virtual meetings this past year to address the challenges that arose with offering our existing programmes as well as new approaches and opportunities for the foundation in the future. I am most grateful to all, including our staff support from Carola van der Hoeff and Rachel van Kesteren and board members of the USA FIP Foundation, for everyone's dedication of time and expertise to our foundation.

On a personal note, the foundation experienced the loss of two incredible pharmacy leaders. John Ware, our former chair, passed away in late December. His contributions to FIP and the foundation and passion for the profession will long be remembered. In addition, we mourned the passing of Joseph Oddis, former FIP president, who helped lead the founding of our foundation and was its first chair in 1993–94. We are most grateful for Joe's vision to create the foundation and initiate our work to help advance research and education that continues today.

The pandemic has caused both disappointments and opportunities with the project work of the foundation this past year. Cancellation of two congresses negatively affected our programme activity, as travel grants and the Ton Hoek scholarship were both cancelled for the year and

most Pharmabridge visits were postponed. We were able to continue the Innovation Research award with the Young Pharmacists Group.

Despite these challenges, our foundation board has used this past year as a time to review our work overall to better define our focus and improve our programme success in the future. Our review has confirmed the importance of the foundation continuing to align with the overall goals of FIP and across the areas of education, practice and science. The new FIP Developmental Goals will also provide a guide to future foundation priorities.

Our foundation board can see opportunities to improve and better connect our work to the needs and priorities of BPP, BPS, FIPEd, the sections and SIGs. We also see opportunities for partnership work with the USA FIP Foundation board, as well as external key stakeholders to advance our programmes.

We greatly appreciate your past commitments to the success of the foundation programmes and your gifts and donations to support our work. Many of you chose to donate your 2021 congress registration fees and we greatly appreciate this support. As we further refine and improve our project work, we welcome your ongoing support and suggestions.

The new year brings opportunities for renewed programming as well as new approaches for achieving growth and success. We look forward to the opportunities and work ahead to continue supporting the important global priorities for FIP and pharmacy.

Prof. Jenelle Sobotka

Janelle Sototka

Chair

FIP Foundation for Education and Research

# PROJECTS AND DEVELOPMENTS

# HEALTH LITERACY/PICTOGRAM PROJECT: COMMUNICATING MEDICATION INSTRUCTIONS TO PEOPLE WITH NO COMMON LANGUAGE

Pictograms give health professionals a means of communicating medication instructions to people with no common language or who are illiterate, or both. Pictograms can also be used for those who have slight cognitive impairment. In 2004, FIP's Military and Emergency Pharmacy Section took over this project, which was created in 1983 by a small group of pharmacists. In 2020, Régis Vaillancourt, FIP pictogram project lead, continued the work started in previous years of creating, testing and validating medication safety pictograms. The foundation has continued to support the FIP pictogram project, designed to make medicines use safer, although progress has been affected by the pandemic.

The international validation study of pharmaceutical pictograms among older adults in Singapore continued in 2020 and academic papers were presented. A similar project started in Malta for low-health-literate elderly patients. Both countries adapted FIP pictograms to be aligned with the cultural differences to meet their populations' needs.

#### Pictograms representing pain

The work started by Dr Vaillancourt in collaboration with the University of Cincinnati, USA, on developing pictograms to represent the sensory and affective qualities of pain, moved forward during 2020. Two online surveys — in English and Polish — were published to further refine the pain pictograms. The foundation awaits the publication of the results of both surveys.

### Simulation to test medication safety pictograms

A study of using simulation to test medication safety pictograms was completed in 2020. The results had not been delivered by the time this report was prepared. The goal of this study is to use simulation to test the impact of pictograms on medication handling. "We hypothesise that pictograms will help healthcare providers avoid medication errors in the administration of injectable drugs. To our knowledge, this is the first study to use simulation to explore the impact of pictograms on medication administration and patient safety," said Dr Vaillancourt.

This study explores the impact of validated pictograms on medicines administration and patient safety using simulation in a clinical environment. "Specifically, we will investigate the impact of the pictograms in preventing medicines administration errors in the emergency department (ED). We decided to test the pictograms using ED simulation scenarios (i.e., trauma patients) given that the majority of medication errors are associated with emergency procedures and intravenous administration," added Dr Vaillancourt.

Thank you to donors who have contributed to this project for your support of this important work to address health literacy. Your ongoing donations are important to continue and expand this work.

# PHARMABRIDGE: PROVIDING EXPERIENTIAL LEARNING TO ADVANCE PHARMACY PRACTICE, SCIENCE AND EDUCATION GLOBALLY

The foundation has continued to support the Pharmabridge programme. This initiative is aimed at strengthening pharmacy services and pharmacy education in low-income and developing countries (LIDCs). It was founded in 1999 by Agathe Wehrli with the main objective of sharing knowledge and experience through two principal initiatives:

**Book donations:** Complimentary copies of the "American Hospital Formulary Service Drug Information" books were sent to every new PharmaBridge registrant from an LIDC by the American Society of Health-System Pharmacists.

**Placements for experiential learning:** The programme links pharmacists from LIDCs with institutions all over the world. This leads to three or four weeks of exchanging experience, resources and training in several domains: pharmacy practice, pharmaceutical science, the pharmaceutical industry and professional pharmacy education.

In early 2020, two pharmacists from Ethiopia and one from Nepal were placed for practice exposure in Ghana and Finland, respectively. Due to travel restrictions, all other planned practice exposures were placed on hold in 2020.



"Formal and informal discussions helped me to align the information and experience how Good Pharmacy Practice (GPP) was implemented. I came to know that GPP is the aspect of quality that comes through continuous involvement. In Nepal more focus is given to the manufacturing of medicines but not to the other activities that can lead to degradation of the medicine during distribution and storage in community pharmacy. This means there is no assurance of quality of the product that reaches the patient. Moreover, the way a patient stores the medicine can also impact the quality of the product. This has increased my enthusiasm to implement GPP back home. I received valuable suggestions, particularly for implementation based on the local context. Since I own a pharmacy I am in a good position to implement GPP locally. Thus, with high motivation and inspiration I am going back and hope to try implementing GPP," reported KC Badri, pharmacist, Nepal.

Over the years, Pharmabridge has helped establish numerous connections for experiential learning to advance pharmacy globally. Please help Pharmabridge continue these efforts by continuing to support the foundation with your donations.

### **GRANTS AND SCHOLARSHIPS**

Foundation grants enable participants to help others to develop skills and knowledge in line with the objectives of the foundation. The grants and scholarship programmes include:

- Travel grants;
- The Ton Hoek scholarship; and
- Foundation/Young Pharmacists Group (YPG) innovation grants.

#### TRAVEL GRANTS

In 2020, the pandemic caused the cancellation of both the Pharmaceutical Sciences World Congress and the FIP World Congress of Pharmacy and Pharmaceutical Sciences. Following this cancellation, the foundation made the decision to cancel all 2020 travel grants. The foundation is preparing a revised grants programme for future release.

#### TON HOEK SCHOLARSHIP

The Ton Hoek scholarship for young leaders permits a young pharmacist or pharmaceutical scientist to travel to an FIP congress in order to develop, or to help others to develop, skills and knowledge in line with the objectives of the foundation, promoting global guidance and inspiration. The award is named after the late Ton Hoek (1955–2012), a former FIP CEO. The 2020 recipient, Lucas Ercolin (pictured right), will receive the scholarship award and be recognised at the 2022 FIP congress planned for Seville, Spain.



#### FOUNDATION/YPG GRANT FOR PROFESSIONAL INNOVATION

The foundation, together with the FIP YPG, awards a grant of EUR 1,000 to encourage innovation in pharmacy by a young pharmacist or pharmaceutical scientist who has limited resources for their own research. The grant supports the implementation of the recipient's project. These projects can stem from any field of pharmacy but should directly or indirectly benefit or improve the health of communities and demonstrate the added value of pharmacy to health.

#### Grant recipient 2020

The 2020 recipient, Dallas Smith (pictured right), is a lecturer of clinical pharmacy and pharmacognosy at the College of Medicine, University of Malawi. Denise Msowoya and Henry Phiri are part of his research team. They assisted in writing the proposal and implemented the initiative, entitled "Evaluation of a pharmacist-led medication therapy management program for patients with hypertension at an outpatient clinic".



This 10-month interventional project will be conducted in three distinct phases. The first phase is a month-long training on hypertension therapeutic treatment and medication therapy management (MTM) for the local Malawian study pharmacist. This grass-roots capacity building will not only ensure a successful project, but also equip the pharmacist to continue this role post-analysis and acquire the ability to train others. Secondly, the ambulatory trained pharmacist will be placed in an outpatient hypertension clinic at a large tertiary hospital in Malawi.

"The pharmacist will provide evidenced-based interventions. Blood pressure changes, adherence, patient satisfaction, and healthcare provider feedback will be compared between these patients and another group of 50 patients who are receiving standard care at the clinic. An analysis will take place at baseline, five months, and 10 months while accounting for various forms of disease severity," said Dr Smith.

The study aims to clinically evaluate the impact an ambulatory pharmacist has on outpatient hypertension outcomes. Armed with the data, the researchers are targeting the advancement of the pharmacy profession in Malawi to a more clinical role while offering the Malawian healthcare system additional support as the country tackles a dual health profile of communicable and non-communicable diseases. Furthermore, this study will assist in fostering relationships with other healthcare providers to encourage cross-professional collaboration in the future.

#### Grant recipient 2019

The 2019 recipient, Shepard Nqobile Mhlaba (pictured right), is a community pharmacist in Harare, Zimbabwe. He is FIP global lead for early career development strategy and a master's degree candidate in health economics at Bindura University of Science and Education in Zimbabwe. Mr Mhlaba presented the findings of his project at the 2020 FIP Virtual congress.



His project investigated the impact of utilising a digital platform for supply chain management in community pharmacy practice. The main objective of the research was to assess the impact of the digital platform on expiry of medicines and business performance. He designed an online supply chain management system for community pharmacies for online ordering, business data analytics, and inventory management with an expiry push notifications alert system. The grant funds were used to hire a web developer, purchase a computer, and pay for web hosting, database and internet services.

Thirty community pharmacies in Harare were enrolled in the study. Preliminary results indicated a significant decrease in quantity of expired medicines per month, a decrease in monthly total cost of expired medicines, and an increase in stock levels and product availability in pharmacies.

"This study is of importance to improving access to medicines which are usually a scarce commodity in developing countries.... The completion of this project would not have been possible without the guidance and support from FIP YPG, my mentor and the foundation at large," explained Mr Mhlaba.

Mr Mhlaba added: "2020 was a difficult year as we were facing a ruthless global pandemic of COVID-19. We had to social distance and practise hygiene to prevent the spread of the virus and also to protect ourselves from the disease. We had to cancel most of our plans and comply with the new regulations. The 2020 FIP Virtual conference was a new experience as we had to connect with our colleges from homes rather than [through] physical meetings we were used to in the previous conferences. FIP Virtual gave me a great opportunity to meet and discuss with fellow pharmacists how to cope with the pandemic by sharing experiences and knowledge. I look forward to my next adventure post pandemic at the world congress".

We look forward to honouring all of the above grant and scholarship recipients at the 2022 congress in Seville, Spain. We greatly appreciate your donations to support continuation of these important programmes.

# **FINANCES**

## Balance sheet as at 31 December 2020 - After appropriation of the result for 2020 (Expressed in EUR)

2020

2019

APITAL AND RESERVES AND LIABILITIES  APITAL AND RESERVES AND LIABILITIES  APITAL CAPITAL AND RESERVES AND LIABILITIES  Ideated funds for future projects  APITAL CAPITAL AND RESERVES AND LIABILITIES  Ideated funds for future projects  54 356  49 356  163 364  162 161  Abilities grants  568  TOTAL CURRENT LIABILITIES  2 516  3 375  AND			2013
Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)			
APITAL AND RESERVES AND LIABILITIES apital and reserves 109 308 112 785 166 180 12785 166 180 12785 166 180 12785 166 180 12785 166 180 12785 166 180 12785 166 180 12785 166 180 12785 166 180 12785 166 180 12785 166 180 12785 166 180 12785 166 180 12785 166 180 12785 166 180 12785 16785		1 250	500
TOTAL ASSETS   166 180   166 180   166 180   166 180   166 180   166 180   166 180   166 180   167 181   166 180   166 180   167 181   167 181   166 180   167 181		5 988	5 222
APPTIAL AND RESERVES AND LIABILITIES  Tapital and reserves 109 308 112 785  Allocated funds for future projects 54 356 49 356  Allocated funds for future projects 55 43 56 49 356  Allocated funds for future projects 55 43 56 162 162 162 162 163 664  Liabilities grants - 568  Total current Liabilities 2 2516 3375  TOTAL CURRENT LIABILITIES 2 2516 3943  TOTAL CAPITAL AND RESERVES AND LIABILITIES 166 180 166 084  Statement of income and expenditure for 2020 (Expressed in EUR)  NCOME 2020 2020  NCOME 2020 2020  NCOME 3 4229 8 547  Development Grant from FIP 5000 5000  TOTAL INCOME 13 429 13 547  EXPENSES  Grants 6 208 14 468  Allocated costs 1500 10 186  Operational costs 1500		158 942	160 362
Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   NCOME	TOTAL ASSETS	166 180	166 084
Capital and reserves         109 308         112 785           Allocated funds for future projects         54 356         49 356           Allocated funds for future projects         54 356         49 356           Liabilities grants         -         568           Other liabilities         2 516         3 375           TOTAL CURRENT LIABILITIES         2 516         3 943           Statement of income and expenditure for 2020 (Expressed in EUR)           NCOME         2020         2019           NOOME         2020         2019           Poevelopment Grant from FIP         5 000         5 000           EXPENSES         3 13 429         13 429           STARTS         6 208         14 468           Allocated costs         1 500         10 186           Operational costs         1 500         10 186           Operational costs         1 1920         31 423           Interest and unrealised change on bonds         14         35           Interest (from)/			
163 664   162 141   162 141   163 664   162 141   163 664   162 141   163 664   162 141   163 664   162 141   163 664   162 141   163 664   163 664   163 664   163 664   163 664   163 664   163 664   163 664   163 664   163 664   163 664   163 664   163 664   163 664   163 664   164		109 308	112 785
Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   Statement of income and expenditure for 2020 (Expressed in EUR)   NCOME		54 356	49 356
Cother liabilities   2 516   3 375		163 664	162 141
Cother liabilities   2 516   3 375			F60
TOTAL CAPITAL AND RESERVES AND LIABILITIES   166 180   166 084		2 516	
Statement of income and expenditure for 2020 (Expressed in EUR)   NCOME	TOTAL CURRENT LIABILITIES		
Statement of income and expenditure for 2020 (Expressed in EUR)   NCOME			
NCOME 2020 2019 NOOME 8 429 8 547 Development Grant from FIP 5 000 5 000 TOTAL INCOME 13 429 13 547  EXPENSES Grants 6 208 14 468 Allocated costs 1500 10 186 Deparational costs 4 212 6 769 TOTAL EXPENSES 11 920 31 423  OPERATING RESULT 1509 (17 876)  Interest and unrealised change on bonds 14 35  NET RESULT BEFORE APPROPRIATION 1523 (17 841)  Appropriation of the result, (from)/to: Allocated funds 5 000 (2 936) FIF Foundation for Edication and research Capital (3 477) (14 905))	TAL AND RESERVES AND LIABILITIES	166 180	166 084
Development Grant from FIP   5 000   5 000     TOTAL INCOME   13 429   13 547     EXPENSES		2020	2019
TOTAL INCOME   13 429   13 547		8 429	8 547
EXPENSES  Grants 6 208 14 468  Allocated costs 1 500 10 186  Operational costs 4 212 6 769  TOTAL EXPENSES 11 920 31 423  OPERATING RESULT 1 509 (17 876)  Interest and unrealised change on bonds 14 35  FINANCIAL RESULT 1 1 523 (17 841)  Appropriation of the result, (from)/to:  Appro			5 000
Appropriation of the result, (from)/to:   Appropriation for Edication and research Capital   14 468   14 468   14 468   1500   10 186   16 208   1500   10 186   16 208   16 208   16 208   16 200   16	TOTAL INCOME	13 429	13 547
Allocated costs 1500 10 186 Operational costs 4212 6 769 TOTAL EXPENSES 11 920 31 423  OPERATING RESULT 1509 (17 876) Interest and unrealised change on bonds 14 35 FINANCIAL RESULT 14 35  Appropriation of the result, (from)/to: Allocated funds 5000 (2 936) FIF Foundation for Edication and research Capital (3 477) (14 905))			
Operational costs 4 212 6 769  TOTAL EXPENSES 11 920 31 423  OPERATING RESULT 1 509 (17 876)  Interest and unrealised change on bonds 14 35  FINANCIAL RESULT 14 35  NET RESULT BEFORE APPROPRIATION 1 523 (17 841)  Appropriation of the result, (from)/to: Appropriation of the result, (from)/to: FIP Foundation for Edication and research Capital (3 477) (14 905))		6 208	14 468
TOTAL EXPENSES 11 920 31 423  OPERATING RESULT 1 509 (17 876)  Interest and unrealised change on bonds 14 35  FINANCIAL RESULT 14 35  NET RESULT BEFORE APPROPRIATION 1 523 (17 841)  Appropriation of the result, (from)/to:  Appropriation of the result, (from)/to:  FINANCIAL RESULT BEFORE APPROPRIATION 5 000 (2 936)  FINANCIAL RESULT BEFORE APPROPRIATION (3 477) (14 905))		1 500	10 186
OPERATING RESULT 1509 (17 876)  Interest and unrealised change on bonds 14 35  FINANCIAL RESULT 14 35  NET RESULT BEFORE APPROPRIATION 1523 (17 841)  Appropriation of the result, (from)/to:  Appropriation of the result, (from)/to:  Allocated funds 5 000 (2 936)  FIP Foundation for Edication and research Capital (3 477) (14 905))		4 212	6 769
NET RESULT BEFORE APPROPRIATION 1523 (17 841)  Appropriation of the result, (from)/to:  Allocated funds 5000 (2 936)  FIF Foundation for Edication and research Capital (3 477) (14 905))	TOTAL EXPENSES	11 920	31 423
NET RESULT BEFORE APPROPRIATION 1 523 (17 841)  Appropriation of the result, (from)/to:  Allocated funds 5 000 (2 936)  FIF Foundation for Edication and research Capital (3 477) (14 905))	OPERATING RESULT	1 509	(17 876)
NET RESULT BEFORE APPROPRIATION 1523 (17 841)  Appropriation of the result, (from)/to:  Allocated funds 5 000 (2 936)  FIP Foundation for Edication and research Capital (3 477) (14 905))			
NET RESULT BEFORE APPROPRIATION 1523 (17 841)  Appropriation of the result, (from)/to:  Allocated funds 5 000 (2 936)  FIP Foundation for Edication and research Capital (3 477) (14 905))		14	
Appropriation of the result, (from)/to: Allocated funds 5 000 (2 936) FIP Foundation for Edication and research Capital (3 477) (14 905))	FINANCIAL RESULT	14	35
Appropriation of the result, (from)/to: Allocated funds 5 000 (2 936) FIP Foundation for Edication and research Capital (3 477) (14 905))			
Allocated funds 5 000 (2 936) FIP Foundation for Edication and research Capital (3 477) (14 905))	NET RESULT BEFORE APPROPRIATION	1 523	35
FIP Foundation for Edication and research Capital (3 477) (14 905))	NET RESULT BEFORE APPROPRIATION	1 523	35
	NET RESULT BEFORE APPROPRIATION		(17 841)
TOTAL APPROPRIATED 1 523 (17 841)		5 000	(17 841) (2 936)
		TOTAL CURRENT LIABILITIES  TAL AND RESERVES AND LIABILITIES  Income and expenditure for 2020 (  TOTAL INCOME  TOTAL EXPENSES  OPERATING RESULT	158 942   TOTAL ASSETS   166 180



# ABOUT THE FIP FOUNDATION FOR EDUCATION AND RESEARCH

The FIP Foundation for Education and Research is a not-for-profit organisation established in 1993. Its main objective is to promote the educational and research ventures of pharmacists and pharmaceutical scientists within the general fields of design, manufacture, distribution and use of medicines for humans and animals.

Its work is sustained by donations and sponsorships, and it is thanks to this support that the profession of pharmacy has benefited through the foundation's research projects, professional advancement opportunities, publications, grants and awards. Your donation will help the foundation continue to create and develop programmes that advance the pharmacy profession.

#### FIP FOUNDATION STRUCTURE:

#### Directors of the foundation in 2020 were:



Mr John Ware (Australia) — chair until November 2020



Prof. Jenelle Sobotka (USA)
— chair from November 2020



Mrs Carola van der Hoeff (Netherlands)
— executive director



Prof. Giovanni Pauletti (USA)

— BPS representative



Ms Ema Paulino (Portugal)
— BPP representative



Dr Régis Vaillancourt (Canada)



Prof. Meindert Danhof (Netherlands)

— director



Prof .Ralph J. Altiere (USA)

— FIPEd representative



Prof. Lee Vermeulen (USA)

— director



Dr Nobuo Yamamoto (Japan)
— director

#### WAYS TO DONATE

The foundation has its own website (<a href="www.fipfoundation.org">www.fipfoundation.org</a>) so that people can find out more about the important projects we support and make direct donations. Donations and sponsorship are essential to our work and the foundation has expanded the ways in which donations can be made to include an online form (up to EUR 1,000) and PayPal, as well as bank transfers and cheques. In addition, if you would like to donate gifts for future FIP congress raffles, please contact <a href="mailto:foundation@fip.org">foundation@fip.org</a>.

If you are interested in making a donation to USA FIP Foundation, please contact: Lee Vermeulen, secretary/treasurer, at <a href="mailto:lee.vermeulen@uky.edu">lee.vermeulen@uky.edu</a>.

It is thanks to the generosity of our donors that we can continue helping to develop the pharmacy profession worldwide.





FIP Foundation for Education and Research Andries Bickerweg 5 2517 JP The Hague The Netherlands

Email: foundation@fip.org

To make a donation, or to find out more about the foundation, please visit: <a href="https://www.fipfoundation.org">www.fipfoundation.org</a>



FIP FOUNDATION FOR EDUCATION AND RESEARCH